Skip to content
PeptideTech
Cart

Home / Research library / Cagrilintide

Peptides

Cagrilintide: molecular data, studies & sources

Cagrilintide is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.

Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review

Molecular formula, weight & structure

Molecular formula (MF)
C194H312N54O59S2
Molecular weight (MW)
4409 g/mol
PubChem compound ID
171397054
Record title
Cagrilintide

Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.

Source: PubChem CID 171397054 · retrieved 2026-09-21

2D molecular structure for Cagrilintide, PubChem CID 171397054
2D depiction from PubChem. Open to inspect the full image. This drawing represents the selected record, not a vendor batch test.
Chemical identifiers and source data
IUPAC name
20-[[(1S)-4-[[(2S)-6-amino-1-[[(4R,7S,10S,13S,16S,19R)-4-[[(2S)-1-[[(2S,3R)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[2-[(2S)-2-[[(2S,3S)-1-[[(2R)-1-[(2R)-2-[(2R)-2-[[(2R,3S)-1-[[(2R)-4-amino-1-[[(2R)-1-[[2-[[(2R)-1-[[(2R)-4-amino-1-[[(2R,3S)-1-[(2R)-2-carbamoylpyrrolidin-1-yl]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxopropan-2-yl]carbamoyl]-16-(2-amino-2-oxoethyl)-7,13-bis[(1R)-1-hydroxyethyl]-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxohexan-2-yl]amino]-1-carboxy-4-oxobutyl]amino]-20-oxoicosanoic acid
InChIKey
LDERDVMBIYGIOI-IZVMHKDJSA-N
SMILES
CC[C@H](C)[C@@H](C(=O)N[C@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)N2CCC[C@@H]2C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H](C(C)C)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](CC(=O)N)C(=O)N[C@H]([C@H](C)O)C(=O)N3CCC[C@@H]3C(=O)N)NC(=O)[C@@H]4CCCN4C(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC6=CNC=N6)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)NC(=O)[C@@H]8CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N8)[C@@H](C)O)C)[C@@H](C)O)CC(=O)N)NC(=O)[C@H](CCCCN)NC(=O)CC[C@@H](C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O
Machine-readable PubChem source
Calculated molecular descriptors
Monoisotopic (exact) mass4406.2515 Da
Heavy atoms309
Hydrogen-bond donors60
Hydrogen-bond acceptors62
Rotatable bonds135
Topological polar surface area1824.5 Ų
Calculated logP (Crippen)-19.06
Rings8
Stereocenters42
Formal charge0

Computed with RDKit from the published SMILES (Crippen logP, topological polar surface area). Calculated descriptors are not measured properties of a supplied batch.

Registered clinical trials

Studies registered on ClinicalTrials.gov that list Cagrilintide as an intervention. Studies that only measure the molecule as a biomarker are excluded. A registration describes a planned or completed protocol; it does not report a result. Active studies are listed first.

40 registered studies matched, 16 currently active or recruiting.

StudyPhase · statusConditionsSponsor · size
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. Once Weekly Versus Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 · start 2026-08-04 · primary completion 2029-09-07Phase 3RecruitingDiabetes Mellitus, Type 2Novo Nordisk A/S80 participants
A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or ObesityNCT07745504 · start 2026-08-04 · primary completion 2027-05-18Phase 3RecruitingOverweight · ObesityNovo Nordisk A/S285 participants
Bioequivalence Study of Cagrilintide B + Placebo Semaglutide I and Cagrilintide D Once Weekly in Participants With Overweight or ObesityNCT07597018 · start 2026-05-18 · primary completion 2027-05-28Phase 1RecruitingObesity · OverweightNovo Nordisk A/S234 participants
Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility StudyNCT07607587 · start 2026-05-29 · primary completion 2027-11-19Phase 1RecruitingObesity · OverweightNovo Nordisk A/S114 participants
Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and FunctionNCT07527195 · start 2026-04-10 · primary completion 2028-04-28Phase 1RecruitingObesityNovo Nordisk A/S100 participants
A Study Investigating the Effect of Cagrilintide on Energy Intake and Appetite in People With Overweight or ObesityNCT07557953 · start 2026-04-30 · primary completion 2027-04-13Phase 1RecruitingOverweight · ObesityNovo Nordisk A/S120 participants
Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or ObesityNCT07411560 · start 2026-02-09 · primary completion 2027-01-26Phase 1RecruitingOverweight · ObeseNovo Nordisk A/S100 participants
Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or ObesityNCT07253285 · start 2026-01-08 · primary completion 2030-03-20Phase 3RecruitingOverweight · ObesityNovo Nordisk A/S460 participants
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or ObesityNCT07220642 · start 2025-11-05 · primary completion 2027-05-11Phase 3Active Not RecruitingObesity · OverweightNovo Nordisk A/S300 participants
Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 DiabetesNCT07220759 · start 2025-11-05 · primary completion 2027-05-12Phase 3Active Not RecruitingOverweight · Obesity · Type 2 DiabetesNovo Nordisk A/S330 participants
Show 30 more registered studies
StudyPhase · statusConditionsSponsor · size
The Effect of Cagrilintide and Semaglutide Combination Treatment Compared to a Weight-loss Inducing Diet on Energy Metabolism in Persons Living With Obesity: an Open-label Randomised StudyNCT07184086 · start 2025-09-26 · primary completion 2027-10-12Phase 1Active Not RecruitingObesityNovo Nordisk A/S80 participants
The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With ObesityNCT07010432 · start 2025-06-12 · primary completion 2028-05-03Phase 1RecruitingObesityNovo Nordisk A/S144 participants
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c. (CagriSema s.c.) Once Weekly for Weight Management and Long-term Weight Maintenance in Participants With ObesityNCT07011667 · start 2025-06-03 · primary completion 2027-03-01Phase 3Active Not RecruitingObesityNovo Nordisk A/S609 participants
Long-term Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Placebo in Participants With ObesityNCT06780449 · start 2025-02-10 · primary completion 2028-08-28Phase 3Active Not RecruitingObesityNovo Nordisk A/S400 participants
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular DiseaseNCT05669755 · start 2023-03-01 · primary completion 2027-09-01Phase 3Active Not RecruitingCardiovascular DiseaseNovo Nordisk A/S7101 participants
Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or ObesityNCT05567796 · start 2022-11-01 · primary completion 2024-10-30Phase 3Active Not RecruitingObesityNovo Nordisk A/S3400 participants
Investigation of Pharmacokinetics of Two Different Presentations of Cagrilintide in Participants With Overweight and ObesityNCT07605052 · start 2026-05-20 · primary completion 2026-08-19Phase 1CompletedOverweight · ObesityNovo Nordisk A/S50 participants
Efficacy and Safety of co Administered Cagrilintide and Semaglutide (CagriSema) Once Weekly Versus Placebo in Participants With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 · start 2025-01-29 · primary completion 2026-06-26Phase 2CompletedDiabetes Mellitus, Type 2 · Diabetic Peripheral NeuropathyNovo Nordisk A/S142 participants
A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.NCT06719011 · start 2024-12-03 · primary completion 2026-07-20Phase 1CompletedObesity · OverweightNovo Nordisk A/S178 participants
Comparing the Pharmacokinetics of Cagrilintide and Semaglutide Following Single Subcutaneous Doses of Different CagriSema Presentations, in a Crossover Manner in Adult Participants With Overweight or ObesityNCT06716307 · start 2024-12-02 · primary completion 2025-03-28Phase 1CompletedObesityNovo Nordisk A/S18 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or BothNCT06534411 · start 2024-11-05 · primary completion 2026-06-02Phase 3CompletedDiabetes Mellitus, Type 2Novo Nordisk A/S1023 participants
Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or ObesityNCT06388187 · start 2024-06-24 · primary completion 2026-04-22Phase 3CompletedObesityNovo Nordisk A/S300 participants
Effect of CagriSema, Semaglutide and Cagrilintide on Insulin Sensitivity and Pancreatic Endocrine Function in Adults With Type 2 DiabetesNCT06403761 · start 2024-05-06 · primary completion 2025-12-28Phase 1CompletedDiabetes Mellitus, Type 2Novo Nordisk A/S158 participants
Effects of NNC0194-0499 Alone and in Combination With Semaglutide, of Semaglutide Alone, and of Cagrilintide Alone and in Combination With Semaglutide on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 · start 2024-05-20 · primary completion 2025-11-21Phase 2CompletedAlcohol-related Liver DiseaseNovo Nordisk A/S270 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or ObesityNCT06131372 · start 2024-04-01 · primary completion 2025-09-24Phase 2CompletedChronic Kidney Disease · Type 2 Diabetes · ObesityNovo Nordisk A/S626 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes as Add on to Once-daily Basal Insulin With or Without MetforminNCT06323161 · start 2024-03-26 · primary completion 2025-09-09Phase 3CompletedType 2 DiabetesNovo Nordisk A/S274 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and ExerciseNCT06323174 · start 2024-03-19 · primary completion 2025-10-01Phase 3CompletedType 2 DiabetesNovo Nordisk A/S189 participants
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment (CagriSema) on Appetite and Functional Brain Activity in People With Overweight or ObesityNCT06267092 · start 2024-02-15 · primary completion 2025-04-07Phase 1CompletedOverweight · ObesityNovo Nordisk A/S164 participants
An Open-label, One-sequence Cross-over, Single-centre Trial, Investigating the Influence of CagriSema on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Atorvastatin in Participants With Overweight or ObesityNCT06289504 · start 2024-02-27 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S34 participants
An Investigation of the Effect of Cagrilintide and Semaglutide Combination Treatment(CagriSema) on Energy Intake, Appetite and Gastric Emptying in People With Overweight or ObesityNCT06207877 · start 2024-02-23 · primary completion 2024-10-16Phase 1CompletedObesityNovo Nordisk A/S62 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorNCT06221969 · start 2024-01-16 · primary completion 2026-03-04Phase 3CompletedType 2 DiabetesNovo Nordisk A/S1024 participants
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With ObesityNCT06131437 · start 2023-11-27 · primary completion 2025-12-08Phase 3CompletedObesityNovo Nordisk A/S809 participants
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorNCT06065540 · start 2023-09-27 · primary completion 2025-11-19Phase 3CompletedType 2 Diabetes MellitusNovo Nordisk A/S2734 participants
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or ObesityNCT05996848 · start 2023-08-15 · primary completion 2025-01-06Phase 3CompletedObesity or OverweightNovo Nordisk A/S300 participants
Efficacy and Safety of Cagrilintide S.C. 2.4 mg in Combination With Semaglutide S.C. 2.4 mg (CagriSema S.C. 2.4 mg/2.4 mg) Once-Weekly in East Asian Participants With Overweight or ObesityNCT05813925 · start 2023-04-03 · primary completion 2025-01-17Phase 3CompletedObesity or OverweightNovo Nordisk A/S331 participants
A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy VolunteersNCT05564104 · start 2023-04-05 · primary completion 2024-09-06Phase 1CompletedHepatic Impairment · Healthy VolunteersNovo Nordisk A/S32 participants
A Thorough QTc Study Evaluating the Effect of Cagrilintide on Cardiac Repolarisation in Healthy ParticipantsNCT05804162 · start 2023-04-12 · primary completion 2023-08-12Phase 1CompletedObesityNovo Nordisk A/S107 participants
Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 DiabetesNCT05394519 · start 2023-02-01 · primary completion 2025-01-28Phase 3CompletedOverweight · Obesity · Type 2 Diabetes MellitusNovo Nordisk A/S1200 participants
Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 DiabetesNCT04982575 · start 2021-08-02 · primary completion 2022-07-07Phase 2CompletedDiabetes Mellitus, Type 2Novo Nordisk A/S92 participants
Investigation of Pharmacokinetics Following Co-administration of Cagrilintide (NNC0174-0833) and Semaglutide Versus Separate Injections in Subjects With Overweight or ObesityNCT04940078 · start 2021-07-07 · primary completion 2022-01-19Phase 1CompletedObesity & OverweightNovo Nordisk A/S40 participants

Registry check 2026-10-01 · Run this search on ClinicalTrials.gov

Human and clinical studies

Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.

  1. Human study · PubMed trial index

    Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

    Garvey WT, Blüher M, Osorto Contreras CK et al. · The New England journal of medicine · 2025

    PMID 40544433 · DOI: 10.1056/NEJMoa2502081

  2. Human study · PubMed trial index

    Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

    Davies MJ, Bajaj HS, Broholm C et al. · The New England journal of medicine · 2025

    PMID 40544432 · DOI: 10.1056/NEJMoa2502082

  3. Human study · PubMed trial index

    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.

    Lau DCW, Erichsen L, Francisco AM et al. · Lancet (London, England) · 2021

    PMID 34798060 · DOI: 10.1016/S0140-6736(21)01751-7

  4. Human study · PubMed trial index

    Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.

    Frias JP, Deenadayalan S, Erichsen L et al. · Lancet (London, England) · 2023

    PMID 37364590 · DOI: 10.1016/S0140-6736(23)01163-7

Preclinical research, reviews & other publications

Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.

  1. Research publication · design requires review

    Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.

    D'Ascanio AM, Mullally JA, Frishman WH et al. · Cardiology in review · 2024 Jan-Feb 01

    PMID 36883831 · DOI: 10.1097/CRD.0000000000000513

Cagrilintide supplier sources

Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.

Cagrilintide for sale: compare prices, sizes and forms from every tracked supplier →

SupplierRecorded packagesExample source listing
American PeptidesUSD10mg Vial1 recorded offers10mg Vial · $170.00Checked Oct 7, 2026Supplier listing
Amino ClubUSD10mg Vial1 recorded offers10mg Vial · $69.99Stale observation · Checked Sep 28, 2026Supplier listing
Amino USAUSD10mg Vial · 5mg Vial2 recorded offers10mg Vial · $102.00Checked Oct 7, 2026Supplier listing
Cenexa LabsUSD10mg Vial1 recorded offers10mg Vial · $159.99Checked Oct 7, 2026Supplier listing

Reference sources & further reading

The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.

Search for additional research

These links run searches; their results have not been individually reviewed and can include unrelated compounds.

Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.

Related research profiles